Melanoma Matters cover art

All Episodes

Melanoma Matters — 89 episodes

#
Title
1

Ep 85: Surgical considerations for TIL

2

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

3

Ep 83: Guest Megan Othus and Time of Day Administration

4

Ep 82: Best of ASCO: 2026

5

Live from ASCO 2026: a preview

6

Ep 81: IGNYTE trial (RP1 + nivo)

7

Ep 80: 2025 Holiday Special

8

Ep 79: coBRIM, COMBI-d 5-year follow-up

9

Ep 78 TRAILER: MEK inhibitor trials

10

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

11

Ep 77: Guest Merrick Ross

12

Ep 76: KEYNOTE 054 7-year follow-up

13

Ep 75: Immune-mediated Myocarditis

14

Ep 74: Best of ESMO 2025: Part 2 of 2

15

Ep 73: Best of ESMO 2025: Part 1 of 2

16

ESMO 2025 preview

17

Ep 72 TRAILER: Quiz show - new drug approvals in 2024

18

Ep 72: Quiz show - new drug approvals in 2024 (yes we're late...)

19

Ep 71: Women in Melanoma manuscript - now with a FACT CHECK!

20

Ep 70: Best of ASCO colon.... 2025 ;)

21

Ep 69: Guest Monty Pal

22

Ep 68: GDF-15 antibody GODFATHER trial

23

Ep 67: SITC white paper on ICI resistance

24

Ep 66: Ponsegromab for cancer cachexia

25

Ep 65: Opdivo Qvantig (subcutaneous formulation)

26

Ep 64: Guest Clare Turnbull Part 2

27

Ep 63: Guest Clare Turnbull Part 1

28

Ep 62: Post PD-1 studies

29

Ep 61: Guest Inge Marie Svane

30

Ep 60: Melanoma & Kidney Cancer w/ Mike Atkins

31

Ep 59: 2024 Reflections

32

Ep 58: Best of 2024: SMR

33

Ep 57: Best of 2024: ESMO

34

Ep 56: Best of 2024: ASCO

35

Ep 55: VIBE Intro - Give Us Your Feedback

36

Ep 54: All things MSLT with Mark Faries

37

Ep 53: Guest Toni Ribas

38

Ep 52: COLUMBUS 7-year follow-up

39

Ep 51: Exercise Oncology and TIL for CNS mets with Allison Betof Warner

40

Ep 50: ADAPT-IT Study

41

Ep 49: Melanoma Patient Network Europe with Bettina Ryll

42

Ep 48: CM 067 Final, 10-year analysis with Jedd Wolchok

43

Ep 47: TRICOTEL with Andreas Schmitt

44

Ep 46: Cemiplimab + Fianlimab (first report)

45

Ep 45: KEYNOTE 006 10 year follow-up

46

Ep 44: Treatment Beyond Progression

47

Ep 43: Mucosal Melanoma

48

Ep 42: RELATIVITY 020

49

Ep 41: Ipi 10 mg/kg v 3 mg/kg

50

Ep 40: CheckMate 238 Post-Recurrence Outcomes

51

Ep 39: LEAP 004 & 003

52

Ep 38: TIL v. Ipi

53

Ep 37: CheckMate 511

54

Ep 36: Indirect comparison CM 067 v RELA 047

55

Ep 35: End of Life care

56

Ep 34: CHOPIN & SCANDIUM trials for Uveal Melanoma

57

Ep 33: Percutaneous Hepatic Infusion for Uveal Melanoma

58

Ep 32: Ipi Nivo for Uveal Melanoma

59

Ep 31: Tebentafusp for Uveal Melanoma (Part Two)

60

Ep 30: Tebentafusp for Uveal Melanoma (Part One)

61

Ep 29: COMBI-AD long-term follow-up (10y)

62

Ep 28: RELATIVITY 048

63

Ep 27: NADINA in practice

64

Ep 26: NADINA w Christian Blank

65

Ep 25: Best of ASCO 2024 with Jeff Weber

66

Ep 24: SECOMBIT

67

Ep 23: DREAMSeq

68

Ep 22: Triplets for BRAF+ melanoma

69

Ep 21: Lifileucel

70

Ep 20: Neoadjuvant Nivolumab + Relatlimab

71

Ep 19: Single-dose of neoadjuvant pembro (UPenn study)

72

Ep 18: SD101 + Pembro

73

Ep 17: TVEC + Ipi

74

Ep 16: MASTERKEY 265

75

Ep 15: OPTiM

76

Ep 14: IMMUNED

77

Ep 13: SWOG S1801

78

Ep 12: PRADO

79

Ep 11: OpACIN-Neo

80

Ep 10: CheckMate 915

81

Ep 09: CheckMate 76K

82

Ep 08: KEYNOTE 716

83

Ep 07: KEYNOTE 054

84

Ep 06: CheckMate 238

85

Ep 05: SWOG S1404

86

Ep 04: EORTC 18071

87

Ep 03: CheckMate-204

88

Ep 02: RELATIVITY-047

89

Ep 01: CheckMate-067